CA3055041A1 - Apparatus and method for assessing and treating cellulite - Google Patents

Apparatus and method for assessing and treating cellulite Download PDF

Info

Publication number
CA3055041A1
CA3055041A1 CA3055041A CA3055041A CA3055041A1 CA 3055041 A1 CA3055041 A1 CA 3055041A1 CA 3055041 A CA3055041 A CA 3055041A CA 3055041 A CA3055041 A CA 3055041A CA 3055041 A1 CA3055041 A1 CA 3055041A1
Authority
CA
Canada
Prior art keywords
cellulite
pcss
severity
scale
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3055041A
Other languages
English (en)
French (fr)
Inventor
Jeffrey Davidson
Michael Mclane
Genzhou LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Ventures Ltd
Original Assignee
Endo Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Ventures Ltd filed Critical Endo Ventures Ltd
Publication of CA3055041A1 publication Critical patent/CA3055041A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/107—Measuring physical dimensions, e.g. size of the entire body or parts thereof
    • A61B5/1079—Measuring physical dimensions, e.g. size of the entire body or parts thereof using optical or photographic means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CA3055041A 2017-03-01 2018-03-01 Apparatus and method for assessing and treating cellulite Pending CA3055041A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762465622P 2017-03-01 2017-03-01
US62/465,622 2017-03-01
US201762485705P 2017-04-14 2017-04-14
US62/485,705 2017-04-14
US201762607188P 2017-12-18 2017-12-18
US62/607,188 2017-12-18
PCT/US2018/020551 WO2018160905A1 (en) 2017-03-01 2018-03-01 Apparatus and method for assessing and treating cellulite

Publications (1)

Publication Number Publication Date
CA3055041A1 true CA3055041A1 (en) 2018-09-07

Family

ID=61768443

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3055041A Pending CA3055041A1 (en) 2017-03-01 2018-03-01 Apparatus and method for assessing and treating cellulite

Country Status (17)

Country Link
US (4) US11123280B2 (https=)
EP (2) EP4591945A3 (https=)
JP (2) JP7558654B2 (https=)
KR (3) KR102610801B1 (https=)
CN (2) CN110545722B (https=)
AU (4) AU2018226820B2 (https=)
BR (1) BR112019018277A2 (https=)
CA (1) CA3055041A1 (https=)
DK (1) DK3589204T3 (https=)
ES (1) ES3036011T3 (https=)
FI (1) FI3589204T3 (https=)
HU (1) HUE072115T2 (https=)
IL (2) IL301796A (https=)
MX (2) MX2023015506A (https=)
PL (1) PL3589204T3 (https=)
PT (1) PT3589204T (https=)
WO (1) WO2018160905A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2802652T (pt) 2012-01-12 2019-09-10 Endo Global Ventures Enzimas de clostridium histolyticum
EP4591945A3 (en) 2017-03-01 2026-04-15 Endo Operations Limited Apparatus and method for assessing and treating cellulite
JP7227918B2 (ja) 2017-03-28 2023-02-22 エンド ベンチャーズ リミテッド コラゲナーゼ産生の改良された方法
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
US20240277595A1 (en) * 2018-09-18 2024-08-22 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
US20220305094A1 (en) * 2019-01-06 2022-09-29 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same
CN118576307A (zh) 2019-03-13 2024-09-03 布鲁瑟姆斯创新有限公司 插入装置以及确定与患者的至少一个目标组织相关联的信息的方法
US11432733B2 (en) 2019-03-13 2022-09-06 Blossom Innovations Tissue detection devices, systems and methods
US20220095925A1 (en) 2019-03-13 2022-03-31 Blossom Innovations, LLC Devices, systems and methods for tissue analysis, location determination and therapy thereof using optical radiation
WO2021108704A1 (en) 2019-11-27 2021-06-03 Blossom Innovations, LLC Devices, systems and methods for tissue analysis, location determination and tissue ablation
CN113033528A (zh) * 2021-05-27 2021-06-25 明品云(北京)数据科技有限公司 一种反馈量表评估方法、系统、设备和介质

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821364A (en) 1966-07-08 1974-06-28 Advance Biofactures Corp Process of producing collagenase
JPS5662229A (en) 1979-10-25 1981-05-28 Asahi Glass Co Ltd Electro-optical dimming panel
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
EP0115974B1 (fr) 1983-01-05 1988-09-07 Institut Pasteur Préparation à activité collagénolytique ayant une activité élevée et compositions pharmaceutiques la contenant
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US5252461A (en) 1990-05-01 1993-10-12 The Regents Of The Univ. Of California Mixed immunoglobulins for detection of rheumatoid factors
CA2047306A1 (en) 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
US5256140A (en) 1992-03-27 1993-10-26 Fallien Cosmeceuticals, Ltd. Composition for levelling skin
WO1994000580A1 (en) 1992-06-22 1994-01-06 Trigen, Inc. Molecular cloning of the genes reponsible for collagenase production from clostridium histolyticum
JP3186881B2 (ja) 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
CA2189646C (en) 1994-06-24 1999-05-25 Francis E. Dwulet A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
CZ280397A3 (cs) 1995-03-16 1998-04-15 Knoll Aktiengesellschaft Nové, definované směsi enzymů pro získávání buněk a pro léčbu poranění
IT1279011B1 (it) 1995-06-15 1997-12-02 Ips Int Prod Services Apparecchiatura per la rilevazione e scelta dei trattamenti della cellulite
US5705170A (en) * 1995-10-24 1998-01-06 Plantech International, Inc. Herbal cellulite treatments
US5989888A (en) 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
ATE272109T1 (de) 1996-11-19 2004-08-15 Roche Diagnostics Gmbh Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US5753785A (en) 1996-12-16 1998-05-19 Fina Technology, Inc. Production of E-B copolymers with a single metallocene catalyst and a single monomer
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
US6335388B1 (en) 1997-10-03 2002-01-01 Lavipharm Laboratories Inc. Prolamine-plant polar lipid composition, its method of preparation and applications thereof
GB9724802D0 (en) 1997-11-24 1998-01-21 Unilever Plc Antiperspirant or deodorant compoistions
US20020036328A1 (en) 1998-11-16 2002-03-28 William R. Richards, Jr. Offset drain fermi-threshold field effect transistors
FR2788682B1 (fr) * 1999-01-26 2001-04-06 Seb Sa Dispositif de thermographie
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
RU2180002C2 (ru) 1999-08-16 2002-02-27 Пермское научно-производственное объединение "Биомед" Способ получения коллагеназы
US6358539B1 (en) 1999-08-20 2002-03-19 Howard Murad Pharmaceutical compositions for reducing the appearance of cellulite
US6280993B1 (en) 1999-08-24 2001-08-28 Ichiro Yamato Gene encoding class I collagenase
ITMI991894A1 (it) * 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
CA2385488C (en) 1999-09-24 2015-07-07 Proteon Therapeutics, Inc. Systems and methods for opening obstructed biological conduits
WO2001078687A1 (en) 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
JP2004528278A (ja) 2000-12-18 2004-09-16 ボード オブ レジェンツ，ザ ユニバーシティー オブ テキサス システム インサイチュヒドロゲルを用いた、局所領域の化学療法および放射線治療
US20030022856A1 (en) 2001-01-30 2003-01-30 The Regents Of The University Of Michigan Method for sustained release local delivery of drugs for ablation of unwanted tissue
ATE302844T1 (de) 2001-07-02 2005-09-15 Nordmark Arzneimittel Gmbh & C Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms
GB0124124D0 (en) 2001-10-08 2001-11-28 Medical Res Council Methods of treatment
SI2241295T1 (sl) * 2002-03-15 2012-11-30 Gen Hospital Corp Naprave za selektivno razbitje maščobnega tkivaz nadzorovanim hlajenjem
JP2003284553A (ja) 2002-03-28 2003-10-07 Seikagaku Kogyo Co Ltd 生理活性タンパク質
BR0215785A (pt) * 2002-06-25 2006-06-06 Ultrashape Inc dispositivos e metodologias uteis para esteticas do corpo
EP1433845A1 (en) 2002-12-23 2004-06-30 Georg-August-Universität Clostridium tetani collagenase and uses thereof
EP1462519A1 (en) 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
US8536315B2 (en) 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
US8147428B2 (en) * 2004-04-16 2012-04-03 University Of Massachusetts Device and method for quantifying edema
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ES2660172T3 (es) 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
DE602005014117D1 (de) 2004-07-07 2009-06-04 Lundbeck As Valby H Neues carbamyliertes epo und verfahren zu dessen herstellung
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
WO2006025226A1 (ja) 2004-08-30 2006-03-09 Daicel Chemical Industries, Ltd. ポリグリセリンモノエーテル及びその製造方法
US20150025420A1 (en) * 2004-10-06 2015-01-22 Guided Therapy Systems, Llc Ultrasound treatment device and methods of use
DE102004060075A1 (de) 2004-12-14 2006-07-06 Merck Patent Gmbh Verfahren zur Herstellung von Onium-Salzen mit Dialkylphosphat-, Dialkylphosphinat oder (O-Alkyl)-alkyl- oder Alkyl-phosphonat-Anionen mit geringem Halogenid-Gehalt
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
CN101107006B (zh) 2005-01-21 2013-09-11 纽约州立大学研究基金会 治疗黏连性关节囊炎的方法
JP2006254876A (ja) 2005-03-18 2006-09-28 Hokkaido Univ Ｌ−トリプトファン製造法
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070003541A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
ITPD20050207A1 (it) 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
US20070031482A1 (en) * 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
JP3122177U (ja) * 2005-09-28 2006-06-08 株式会社資生堂 セルライトの診断基準シート
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
EA200802090A1 (ru) * 2006-03-31 2010-04-30 ДСМ АйПи АССЕТС Б.В. Новое применение соединений и комбинаций соединений для улучшения внешнего вида
WO2008100833A2 (en) 2007-02-13 2008-08-21 Auxilium International Holdings, Inc. Production of recombinant collagenases colg and colh in escherichia coli
WO2008101406A1 (en) 2007-02-14 2008-08-28 Yolare Dermaceuticals, Llc Modified mutant collagenase and it's use in fat melting and in scar reduction
EP2152225A1 (en) * 2007-05-11 2010-02-17 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Gel useful for the delivery of cosmetic active ingredients
US9987221B2 (en) 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
US20110262508A1 (en) 2007-11-07 2011-10-27 Paul Michael Watt Antimicrobial compositions, formulations and uses thereof
US20100159564A1 (en) 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
ES2388219T3 (es) 2008-06-02 2012-10-10 F. Hoffmann-La Roche Ag Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
JP5421366B2 (ja) 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
US8380531B2 (en) 2008-07-25 2013-02-19 Invivodata, Inc. Clinical trial endpoint development process
EP2369956A1 (en) * 2008-10-22 2011-10-05 Allergan, Inc. Clinical assessment scales and methods
US20110217252A1 (en) * 2008-11-11 2011-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
ES2531402T3 (es) 2008-11-19 2015-03-13 Meiji Seika Pharma Co Ltd Colagenasa de fusión a la que se une una marca de afinidad, y método para producir la misma
IT1397646B1 (it) 2009-12-15 2013-01-18 Seidita Collagenasi ricombinanti di c. histolyticum e metodo per la loro produzione.
US9132199B2 (en) 2010-03-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Reverse thermal gels and uses therefor
US20130195828A1 (en) 2010-04-14 2013-08-01 Northwestern University Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques
US20120046576A1 (en) * 2010-08-19 2012-02-23 Medicis Pharmaceutical Corporation Mid-face aesthetic scale and related methods
US20130217789A1 (en) 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
ES2385239B1 (es) 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
WO2012125948A1 (en) 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
TWI461214B (zh) 2011-06-13 2014-11-21 Univ Chang Gung Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases
KR102043476B1 (ko) * 2011-10-17 2019-11-12 사운드 써지칼 테크놀로지 엘엘씨 셀룰라이트를 처리하기 위한 초음파 프로브
JP2014530873A (ja) 2011-10-21 2014-11-20 オーキシリウム インターナショナル ホールディングス，インコーポレイテッド Ｅｆｐの治療または低減方法
PT2802652T (pt) 2012-01-12 2019-09-10 Endo Global Ventures Enzimas de clostridium histolyticum
WO2013112974A1 (en) * 2012-01-27 2013-08-01 Revance Therapeutics, Inc. Methods and assessment scales for measuring wrinkle severity
US9933436B2 (en) * 2012-09-07 2018-04-03 Shiseido Company, Ltd. Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator
US20160000890A1 (en) 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
EP2968107B1 (en) * 2013-03-15 2019-05-08 Mary Kay, Inc. Cosmetic compositions and uses thereof
EP3834840B8 (en) * 2013-03-15 2025-09-17 Endo Biologics Limited Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
RU2662356C1 (ru) * 2014-06-27 2018-07-25 Медитокс Инк. Способы и композиции на основе желчных кислот и их солей для уменьшения количества жира
AU2017218522A1 (en) 2016-02-08 2018-08-23 OutcomeMD, Inc. Determining a wellness, improvement, or effectiveness score
ES2886651T3 (es) * 2016-10-28 2021-12-20 Merz Pharma Gmbh & Co Kgaa Tratamiento cosmético de la celulitis
EP4591945A3 (en) 2017-03-01 2026-04-15 Endo Operations Limited Apparatus and method for assessing and treating cellulite
JP7227918B2 (ja) 2017-03-28 2023-02-22 エンド ベンチャーズ リミテッド コラゲナーゼ産生の改良された方法

Also Published As

Publication number Publication date
EP3589204A1 (en) 2020-01-08
MX2023008072A (es) 2023-07-17
AU2024201429B2 (en) 2025-04-24
DK3589204T3 (da) 2025-06-30
EP4591945A3 (en) 2026-04-15
KR20230003601A (ko) 2023-01-06
JP2020511284A (ja) 2020-04-16
HUE072115T2 (hu) 2025-10-28
CN115969318A (zh) 2023-04-18
PT3589204T (pt) 2025-07-18
US11123280B2 (en) 2021-09-21
WO2018160905A1 (en) 2018-09-07
PL3589204T3 (pl) 2025-08-11
JP2023120246A (ja) 2023-08-29
AU2022271390B2 (en) 2024-01-18
JP7558654B2 (ja) 2024-10-01
US20240041744A1 (en) 2024-02-08
FI3589204T3 (fi) 2025-07-03
IL301796A (en) 2023-05-01
KR102610801B1 (ko) 2023-12-05
BR112019018277A2 (pt) 2020-06-30
US12403081B2 (en) 2025-09-02
AU2022271390A1 (en) 2022-12-15
AU2025206433A1 (en) 2025-08-07
NZ756787A (en) 2025-08-29
AU2018226820A1 (en) 2019-09-19
CN110545722B (zh) 2023-02-03
EP4591945A2 (en) 2025-07-30
US11813347B2 (en) 2023-11-14
US20180250217A1 (en) 2018-09-06
AU2024201429A1 (en) 2024-03-21
CN110545722A (zh) 2019-12-06
US20250352450A1 (en) 2025-11-20
ES3036011T3 (en) 2025-09-11
IL268985A (en) 2019-10-31
MX2023015506A (es) 2024-01-22
EP3589204B1 (en) 2025-04-16
KR20250021648A (ko) 2025-02-13
AU2018226820B2 (en) 2022-12-08
US20210386644A1 (en) 2021-12-16
KR20190126341A (ko) 2019-11-11

Similar Documents

Publication Publication Date Title
US12403081B2 (en) Method of assessing and treating cellulite
Camargo et al. Botulinum toxin type A for facial wrinkles
Makharita et al. Ultrasound-guided pulsed radiofrequency in the management of thoracic postherpetic neuralgia: a randomized, double-blinded, controlled trial
Zane et al. A randomized split-face clinical trial of photodynamic therapy with methyl aminolevulinate versus ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and scalp
Ragavendran et al. Effects of topical combinations of clonidine and pentoxifylline on capsaicin-induced allodynia and postcapsaicin tourniquet-induced pain in healthy volunteers: a double-blind, randomized, controlled study
HK40128003A (en) Apparatus and method for assessing and treating cellulite
HK40016426B (en) Apparatus and method for assessing and treating cellulite
HK40016426A (en) Apparatus and method for assessing and treating cellulite
JP2026074227A (ja) セルライトを評価及び処置するための装置及び方法
NZ796433A (en) Apparatus and method for assessing and treating cellulite
Almohideb Management patterns for skin aging among Saudi dermatologists: a questionnaire-based study
Watchmaker et al. Deoxycholic acid in aesthetic medicine
HK40089867A (zh) 用於评估和治疗橘皮组织的装置和方法
HK40019032A (en) Apparatus and method for assessing and treating cellulite
HK40019032B (en) Apparatus and method for assessing and treating cellulite
Hammad et al. Assessment of Double Chin with Exercises and Mesotherapy
Lopresti et al. The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study
Braun Panfacial Botulinum Toxin Improves Patient Retention

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220324

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250725

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260109

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260109

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20260218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260312

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260317

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260317